Substituted pyrrolo[3,2-d]pyrimidines and pyrazolo[4,3-d]pyrimidines as tyrosine kinase inhibitors
申请人:Shenzhen TargetRx, Inc.
公开号:US11186578B2
公开(公告)日:2021-11-30
A fused bicyclic compound having an effect in inhibition of the activity of a tyrosine kinase, and preparation, compositions, and uses thereof are disclosed. In particular, compounds of formula (I) and (II), or a pharmaceutically acceptable salt, a stereoisomer, a solvate, a hydrate, a polymorph, a prodrug or an isotopic variation thereof, as well as a pharmaceutical composition including the same are disclosed. Compounds disclosed herein are substituted pyrrolo[3,2-d]pyrimidines and are selective irreversible inhibitors of Bruton's tyrosine kinase. The described compounds can therefore be used for preventing or treating diseases such as inflammation, autoimmune diseases (such as rheumatoid arthritis), xenogeneic immune diseases and cancers.
本发明公开了一种具有抑制酪氨酸激酶活性作用的融合双环化合物及其制备方法、组合物和用途。特别是公开了式(I)和(II)化合物,或其药学上可接受的盐、立体异构体、溶解物、水合物、多晶型物、原药或同位素变体,以及包括其在内的药物组合物。本文公开的化合物是取代的吡咯并[3,2-d]嘧啶,是布鲁顿酪氨酸激酶的选择性不可逆抑制剂。因此,所述化合物可用于预防或治疗炎症、自身免疫性疾病(如类风湿性关节炎)、异种免疫性疾病和癌症等疾病。